Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00314964 · ClinicalTrials.gov registry record · Phase 2
Study Evaluating PD-0299685 for the Treatment of Vasomotor Symptoms (Hot Flashes / Flushes) Associated With Menopause
A Phase 2 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 2
- Development phase
- 527
- Enrollment target
NCT00314964: Completed Phase 2 study, sponsored by Pfizer.
NCT00314964 is a Phase 2 study that has completed, run by Pfizer. The registered enrollment target is 527 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (296% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00314964, a Phase 2 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 527 participants
- Enrollment target
Study Summary
The primary purpose of this study is to determine if PD-0299685 is effective and safe in the treatment of vasomotor symptoms (hot flashes / flushes) associated with menopause.
Interventions
- DRUG PD-0299685
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 527 participants |
| Start Date | 2006-08 |
| Est. Completion | 2007-07 |
| Phase | Phase 2 |
What the finished NCT00314964 record still lists
NCT00314964 is an interventional study that assigns participants to a tested intervention. The registered 527 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (296% higher).
The record links to 0 conditions, and to 1 intervention - of which PD-0299685 is the first listed.
NCT00314964 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00314964 about?
NCT00314964 is a clinical study titled "Study Evaluating PD-0299685 for the Treatment of Vasomotor Symptoms (Hot Flashes / Flushes) Associated With Menopause". The primary purpose of this study is to determine if PD-0299685 is effective and safe in the treatment of vasomotor symptoms (hot flashes / flushes) associated with menopause.
What is the current status of trial NCT00314964?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 527 participants. The study started on 2006-08. Estimated completion is 2007-07.
What interventions are being tested in trial NCT00314964?
The interventions under investigation include: PD-0299685 (DRUG).
Who is sponsoring clinical trial NCT00314964?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00314964's enrollment target sits among peer trials
527 65th of 2000 higher than 1,936 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05373017 · 528 participants · NA
Delirium and Neuropsychological Recovery Among Emergency General Surgery Survivors
- NCT05634252 · 528 participants · Phase 3
Undergraduate Skin Cancer Prevention Trial
- NCT06383273 · 528 participants · Phase 3
A Study to Evaluate Efficacy and Safety of MELT-300 for Procedural Sedation in Subjects Undergoing Cataract Extraction With Lens Replacement (CELR)
- NCT06470243 · 528 participants · Phase 3
Testing Whether the Addition of Carboplatin Chemotherapy to Cabazitaxel Chemotherapy Will Improve Outcomes Compared to Cabazitaxel Alone in People With Castrate-Resistant Prostate Cancer That Has Spread Beyond the Prostate to Other Parts of the Body
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia